Patient characteristics
| . | Overall (N = 77) . | BKV-negative controls (n = 44) . | BKV positive (n = 33) . | P* . |
|---|---|---|---|---|
| Age at HCT, median (range), y | 53 (20-73) | 55 (20-73) | 51 (20-67) | .077 |
| Sex | .009 | |||
| Male | 47 (61.0) | 21 (47.7) | 26 (78.8) | |
| Female | 30 (39.0) | 23 (52.3) | 7 (21.2) | |
| Diagnosis | .053 | |||
| AML | 33 (42.8) | 25 (56.8) | 8 (24.2) | |
| NHL | 14 (18.2) | 5 (11.4) | 9 (27.3) | |
| MDS/MPD | 10 (13.0) | 4 (9.1) | 6 (18.2) | |
| ALL | 7 (9.1) | 4 (9.1) | 3 (9.1) | |
| CLL/SLL/PLL | 7 (9.1) | 3 (6.8) | 4 (12.1) | |
| Aplastic anemia | 2 (2.6) | 0 (0.0) | 2 (6.1) | |
| CML | 2 (2.6) | 2 (4.5) | 0 (0.0) | |
| HD | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| MM | 1 (1.3) | 1 (2.3) | 0 (0.0) | |
| HLA matching† | .958 | |||
| Matched related donor | 22 (28.6) | 12 (27.3) | 10 (30.3) | |
| Matched unrelated donor | 43 (55.8) | 25 (56.8) | 18 (54.5) | |
| Mismatched unrelated donor | 12 (15.6) | 7 (15.9) | 5 (15.2) | |
| Cell source | .887 | |||
| Peripheral blood stem cells | 67 (87.0) | 39 (88.6) | 28 (84.8) | |
| Double cord | 6 (7.8) | 3 (6.8) | 3 (9.1) | |
| Bone marrow | 4 (5.2) | 2 (4.6) | 2 (6.1) | |
| Conditioning regimen | .497 | |||
| Reduced intensity | 41 (53.2) | 25 (56.8) | 16 (48.5) | |
| Myeloablative | 36 (46.8) | 19 (43.2) | 17 (51.5) | |
| Conditioning drugs | .284 | |||
| Bu/Flu | 37 (48.0) | 24 (54.5) | 13 (39.35) | |
| Cy/TBI | 27 (35.1) | 14 (31.8) | 13 (39.35) | |
| Flu/Mel/ATG | 5 (6.5) | 3 (6.8) | 2 (6.1) | |
| Bu/Cy | 3 (3.9) | 1 (2.3) | 2 (6.1) | |
| Bu/Flu/ATG | 2 (2.6) | 2 (4.6) | 0 (0.0) | |
| Flu/Cy/ATG/TBI | 2 (2.6) | 0 (0.0) | 2 (6.1) | |
| Flu/Mel | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| GVHD prophylaxis | .606 | |||
| Tac/MTX | 38 (49.3) | 22 (50.0) | 16 (48.5) | |
| Tac/Sir | 17 (22.1) | 11 (25.0) | 6 (18.2) | |
| Tac/Sir/MTX | 16 (20.8) | 9 (20.4) | 7 (21.2) | |
| Tac/Sir/MMF/MTX | 3 (3.9) | 1 (2.3) | 2 (6.1) | |
| Tac/MMF | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| Tac/MMF/MTX | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| Tac/Sir/MMF | 1 (1.3) | 1 (2.3) | 0 (0.0) | |
| Acute GVHD grades 2-4 | 37 (48.1) | 18 (40.9) | 19 (57.6) | .172 |
| Chronic GVHD | 33 (42.9) | 20 (57.1) | 13 (41.9) | .324 |
| . | Overall (N = 77) . | BKV-negative controls (n = 44) . | BKV positive (n = 33) . | P* . |
|---|---|---|---|---|
| Age at HCT, median (range), y | 53 (20-73) | 55 (20-73) | 51 (20-67) | .077 |
| Sex | .009 | |||
| Male | 47 (61.0) | 21 (47.7) | 26 (78.8) | |
| Female | 30 (39.0) | 23 (52.3) | 7 (21.2) | |
| Diagnosis | .053 | |||
| AML | 33 (42.8) | 25 (56.8) | 8 (24.2) | |
| NHL | 14 (18.2) | 5 (11.4) | 9 (27.3) | |
| MDS/MPD | 10 (13.0) | 4 (9.1) | 6 (18.2) | |
| ALL | 7 (9.1) | 4 (9.1) | 3 (9.1) | |
| CLL/SLL/PLL | 7 (9.1) | 3 (6.8) | 4 (12.1) | |
| Aplastic anemia | 2 (2.6) | 0 (0.0) | 2 (6.1) | |
| CML | 2 (2.6) | 2 (4.5) | 0 (0.0) | |
| HD | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| MM | 1 (1.3) | 1 (2.3) | 0 (0.0) | |
| HLA matching† | .958 | |||
| Matched related donor | 22 (28.6) | 12 (27.3) | 10 (30.3) | |
| Matched unrelated donor | 43 (55.8) | 25 (56.8) | 18 (54.5) | |
| Mismatched unrelated donor | 12 (15.6) | 7 (15.9) | 5 (15.2) | |
| Cell source | .887 | |||
| Peripheral blood stem cells | 67 (87.0) | 39 (88.6) | 28 (84.8) | |
| Double cord | 6 (7.8) | 3 (6.8) | 3 (9.1) | |
| Bone marrow | 4 (5.2) | 2 (4.6) | 2 (6.1) | |
| Conditioning regimen | .497 | |||
| Reduced intensity | 41 (53.2) | 25 (56.8) | 16 (48.5) | |
| Myeloablative | 36 (46.8) | 19 (43.2) | 17 (51.5) | |
| Conditioning drugs | .284 | |||
| Bu/Flu | 37 (48.0) | 24 (54.5) | 13 (39.35) | |
| Cy/TBI | 27 (35.1) | 14 (31.8) | 13 (39.35) | |
| Flu/Mel/ATG | 5 (6.5) | 3 (6.8) | 2 (6.1) | |
| Bu/Cy | 3 (3.9) | 1 (2.3) | 2 (6.1) | |
| Bu/Flu/ATG | 2 (2.6) | 2 (4.6) | 0 (0.0) | |
| Flu/Cy/ATG/TBI | 2 (2.6) | 0 (0.0) | 2 (6.1) | |
| Flu/Mel | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| GVHD prophylaxis | .606 | |||
| Tac/MTX | 38 (49.3) | 22 (50.0) | 16 (48.5) | |
| Tac/Sir | 17 (22.1) | 11 (25.0) | 6 (18.2) | |
| Tac/Sir/MTX | 16 (20.8) | 9 (20.4) | 7 (21.2) | |
| Tac/Sir/MMF/MTX | 3 (3.9) | 1 (2.3) | 2 (6.1) | |
| Tac/MMF | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| Tac/MMF/MTX | 1 (1.3) | 0 (0.0) | 1 (3.0) | |
| Tac/Sir/MMF | 1 (1.3) | 1 (2.3) | 0 (0.0) | |
| Acute GVHD grades 2-4 | 37 (48.1) | 18 (40.9) | 19 (57.6) | .172 |
| Chronic GVHD | 33 (42.9) | 20 (57.1) | 13 (41.9) | .324 |
Unless noted otherwise, data are n (%).
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; BKV, BK virus; Bu, busulfan; CLL/SLL/PLL, chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic leukemia; CML, chronic myeloid leukemia; Cy, cyclophosphamide; Flu, fludarabine; HD, Hodgkin disease; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; Mel, melphalan; MM, multiple myeloma; MMF, mycophenolate mofetil; MTX, methotrexate; NHL, non-Hodgkin lymphoma; Sir, sirolimus; Tac, tacrolimus; TBI, total body irradiation.
The Mann-Whitney U test was used for quantitative variables, and the Fisher’s exact test and Pearson’s χ2 test were used for qualitative variables.
Matching was done at the 5-loci level (HLA-A/HLA-B/HLA-C/HLA-DRB1/HLA-DQB1).